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Wi
PaTHE FOLLOWING iFORUM DEBATE FEATURES 3 VIEWPOINTS related to the most practical and effective
imaging strategy for guiding transcatheter aortic valve replacement (TAVR). Kronzon, et al. provide evidence that
enhanced analysis of aortic valve anatomy and improved appreciation of complications mandate the use of transeso-
phageal echocardiography as front-line imaging modality for ALL patients undergoing TAVR. On the other hand, Saric and
colleagues compare and contrast the approach of performing TAVR under transthoracic guidance. Lastly, Kasel and
co-workers provide preliminary evidence that TAVR could be performed under ﬂuoroscopic guidance without the need
for additional imaging technique. Although the use of less-intensive sedation or anesthesia might reduce the procedural
time, we need more randomized data to establish the most cost-effective approach in guiding TAVR.TEE for TAVR Guidance
Itzhak Kronzon, MD, Vladimir Jelnin, MD,
Carlos E. Ruiz, MD, PHD
Surgical aortic valve replacement (SAVR) is considered
the treatment of choice in symptomatic patients with
severe aortic stenosis. However, one-third of these pa-
tients are denied surgery because of advanced age,
frailty, comorbidities, and conditions known to increase
the risk of this major cardiac surgery.
Transcatheter aortic valve replacement (TAVR)
offers many of these patients another less traumatic
option that does not require thoracotomy and car-
diopulmonary bypass. When surgery is considered
contraindicated, the outcome of patients who had
undergone TAVR was better than in patients whow York, New York; Munich, Germany; Augsburg, Germany; and Milan,
ener Cardiovascular Institute, Mount Sinai Medical Center, One Gustave
rtho.Sengupta@mountsinai.org.were treated medically (without valve replacement).
In addition, high-risk patients randomized to TAVR
had outcomes similar to those of high-risk patients
randomized to SAVR (1).
TAVR is usually performed with the support
of various cardiac imaging modalities. Fluoroscopy is
almost always used and is frequently used along
with coronary angiography and aortography. Pre-
procedural transthoracic Doppler echocardiography
is almost always used to establish the diagnosis
of severe aortic stenosis. It is also used sometimes to
assess, guide, and monitor the TAVR procedure.
Other modalities frequently used include
transesophageal echocardiography (TEE), and multi-
detector computed tomography. Transthoracic echo-
cardiography (TTE) is suboptimal in many patients.
It is especially difﬁcult in patients in the supineItaly. Dr. Partho P. Sengupta, Zena and Michael A.
L. Levy Place, New York, New York 10029. E-mail:
FIGURE 1 TTE vs. TEE in Aortic Annulus Diameter Measurement
The diameter of the aortic annulus (pink line) measured by the transthoracic echocardi-
ography image (A) (2.2 cm) is much smaller than the diameter measured by
transesophageal echocardiography (B) (3.0 cm).
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362position (as is the case during TAVR) and in
patients with emphysema, chest wall incisions, and
deformities.
In many laboratories, TEE is considered the “bread
and butter” modality of imaging during TAVR. The
higher spatial resolution produces image quality
that is far superior to that of images obtained by
TTE. This includes improved analysis of aortic valve
anatomy such as the bicuspid valve and better iden-
tiﬁcation of intracardiac masses (2).
Aortic plaques can be seen on TEE (and only rarely
on TTE). Their identiﬁcation is important because
large, mobile aortic debris may be a contraindication
to catheter manipulation at their site.
With surgical ﬁndings as the gold standard, mea-
surements obtained by TEE are signiﬁcantly more
accurate than those obtained by TTE (3). This accu-
racy is extremely important in the deﬁnition of the
aortic annulus dimensions. Inaccurate evaluation of
the annulus size may lead to serious complications.
Oversizing of the annulus may result in the selection
of valves of larger dimensions and may lead to
annulus rupture. Undersizing may lead to device
migration, paravalvular leak, and valve embolization
(Figure 1) (4).
After TAVR is performed, it is important to eval-
uate the presence of aortic regurgitation because re-
sidual aortic regurgitation (especially more than 1þ) is
associated with a worse outcome (5). In addition
to the severity, it is also important to determine
whether the aortic regurgitation is a paravalvular
leak or through the prosthetic valve leaﬂets. These 2
conditions may be handled differently. The site and
details of aortic insufﬁciency cannot be accurately
identiﬁed by ﬂuoroscopy with contrast injection orby TTE. Aortic insufﬁciency can be much better
assessed by TEE.
TEE is also useful in the evaluation of post-
procedure complications. Such complications in-
clude wall motion abnormalities due to coronary
occlusion, cardiac tamponade due to right ventricular
laceration by the pacing wire, aortic laceration,
dissection, or intramural hematoma, some of which
cannot be seen with TTE.
Although 3-dimensional (3D) TTE is feasible
and available, its images are suboptimal. Accurate
assessment of the cumbersome 3D shape of the left
ventricular outﬂow tract–aortic root–aortic valve
complex is frequently not of diagnostic quality. On
the other hand, 3D TEE, now available with most
modern echocardiographic equipment, enables the
imager to reconstruct all the aortic valve components,
with accurate measurement of the aortic annulus
that is as accurate as that with contrast multidetector
computed tomography, now considered by many to
be the gold standard for determining annulus size
(Figure 2). 3D TEE is also useful in the evaluation of
the distance between the aortic annulus and the
coronary ostia (especially the ostium of the left main
coronary artery). The short distance between the
annulus and the ostium or a long, bulky left coronary
cusp may result in ostial occlusion and acute left
ventricular ischemic insult (6).
3D TEE is also capable of showing the location of
the catheter tip and of the longer intracardiac portion
of the catheter (7).
3D TEE is now a part of the new, now commercially
available, image fusion software and hardware.
This equipment (Echonavigator, Philips Healthcare,
Best, the Netherlands) is capable of superimposing
the real-time 2-dimensional or 3D transesophageal
echocardiographic images on real-time ﬂuoroscopic
images (Figures 3 and 4).
After registration, scale adjustment, and landmark
positioning, this fusion technology allows better un-
derstanding of the anatomy (such as the location
of the aortic annulus on the ﬂuoroscopy screen,
guiding catheters and devices, and post-deployment
evaluation. This ﬁeld is rapidly developing, improv-
ing, and constantly changing (8). It appears that
fusion imaging may lead to shorter and safer trans-
catheter procedures, including TAVR.
In conclusion, TEE is the guiding technique of
choice for TAVR. Although still requiring sedation
or even general anesthesia, it provides real-time
high-quality images and accurate measurements
that result in better pre-procedural assessment, pro-
cedural guidance, and post-procedural monitoring of
procedure results and possible complications.
FIGURE 2 3D Echo for Accurate Aortic Annulus Dimensions Measurement
3D-TEE is performed over zoom mode to acquire loops of narrowest possible depth with
adjustment of lateral and elevation width. Transverse (left-sided panels), sagittal (middle
panels) and coronal (right-sided panels) planes are outlined in green, red, and blue
colored lines and planes, respectively. The positions of the red and blue lines are opti-
mized such that they intersect at the center of the opened valve (A). The red line is aligned
through the right coronary cusp to develop the reference sagittal plane (B). Similarly, the
blue line is aligned through the left coronary cusp to develop the reference coronal plane
(C). The blue and green lines are then rotated in the sagittal frame (E). This orients the
sagittal (E) and coronal (F) planes parallel to the long axis of aorta, and delineates the
transverse plane along the short axis view of the aortic root (D). The green line is moved
towards the LV outﬂow tract so that it arrives at the hinge point of the right coronary cusp
(H). The annulus is often oval in appearance. The short and long diameters are then
measured on the transverse plane (J). The red and blue lines can be rotated to ensure that
the transverse plane passes through the 3 hinge points, the lowest point of insertions of
the 3 aortic cusps. Curved arrows refer to the direction of rotation. Straight arrows refer
to direction of linear displacement. The asterisks indicate the location of commissures
between the aortic leaﬂets. 3D ¼ 3-dimensional; LCC ¼ left coronary cusp; NCC ¼ non-
coronary cusp; RCC ¼ right coronary cusp; TEE ¼ transesophageal echocardiography.
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363Transthoracic Echocardiography
for TAVR
Muhamed Saric, MD, PHD, Mathew Russell Williams, MD
Transcatheter aortic valve replacement (TAVR) proce-
dure requires the coordinated effort and expertise of the
entire TAVR team, including interventionalists, anes-
thesiologists, and imaging specialists. At any TAVR
stage, the choice of a periprocedural imaging technique
(transthoracic vs. transesophageal echocardiography,
ﬂuoroscopy, computed tomography, and so on) should
not be governed by the technique’s inherent imaging
strengths alone, but rather whether such an imaging
technique provides a proper balance of diagnostic utility
and safety in the larger context of a TAVR procedure.
Since the ﬁrst human TAVR in France by Alain
Cribier and colleagues (9) in 2002, echocardiography
has played 3 important roles: 1) identiﬁcation of
appropriate candidates for TAVR; 2) intraprocedural
guidance; and 3) assessment of post-procedural suc-
cess. In the initial TAVR experience, a dichotomous
pattern of echocardiographic evaluation was devel-
oped: a pre-procedural use of transthoracic echocar-
diography (TTE), and an intraprocedural use
transesophageal echocardiography (TEE) in conjunc-
tion with general anesthesia (GA).
More recently, GA is being replaced with less
invasive forms of anesthesia—collectively referred to
as monitored anesthesia care (MOC)—which typically
consists of intravenous injection of propofol or
dexmedetomidine for sedation, and opioids for
analgesia. MOC has been shown, for instance, in a
meta-analysis of 1,542 TAVR patients enrolled in
nonrandomized trials to provide anesthesia care that
is noninferior to GA and may be associated with
reduced procedural time and shorter hospital stay
(10). Because MOC typically precludes TEE, the
question arises whether TTE can replace TEE for
intraprocedural guidance of TAVR. In this review, we
argue that TTE in appropriate patients can provide
diagnostic echocardiographic imaging before, during,
and after TAVR. Relative advantages and disadvan-
tages of TTE versus TEE in TAVR guidance are sum-
marized in Table 1.
TTE FOR PRE-PROCEDURAL TAVR PLANNING. .Pre-
procedural evaluation includes establishing the
diagnosis of severe aortic stenosis; characterization
of the left ventricular outﬂow tract (LVOT) and aortic
root anatomy; and assessment of all other cardiac
parameters that might impact TAVR, such as left
ventricular function, concomitant valvular lesions,
and intracardiac pressures. All recent guidelinesstipulate that 2-dimensional (2D) and Doppler TTE
are the principle means of establishing the presence,
severity, and etiology of aortic stenosis, assessing its
impact on cardiac anatomy and function, and
determining prognosis and timing of valve inter-
vention (11).
TTE can also provide important information on
LVOT and aortic root anatomy relevant to TAVR.
Concomitant LVOT obstruction that is due to
FIGURE 3 Fusion Imaging
(A) Midesophageal short axis (left) and long axis (right). (B) The long- and short-axis views shown simultaneously. (C) Transesophageal
echocardiography (TEE), ﬂuoroscopy fusion. The 2-dimensional TEE images are superimposed in real time on the ﬂuoroscopic images. The exact
location of structures such as the aortic annulus (yellow ellipse), a transvalvular wire (arrow), and the oriﬁce of the left main coronary
(pink dot) were marked on the TEE images and appear simultaneously on the ﬂuoroscopic screen. Abbreviations as in Figure 2.
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364hypertrophy of the basal interventricular septum may
be a contraindication for TAVR because it may pre-
vent proper valve deployment. TTE can also deter-
mine the number of aortic valve cusps, which is
important in TAVR planning because bicuspid aortic
valve stenosis may be considered a contraindication
for TAVR. TTE may also provide aortic root mea-
surements relevant to choosing the size and type of a
TAVR prosthesis, such as the annular diameter and
the measurements of the sinuses of Valsalva, sino-
tubular junction, and the ascending aorta.
In the initial TAVR experience, the valve size
was often chosen based on the sagittal (ante-
roposterior) annular diameter measured typically by
2D TTE or TEE. However, shortcomings of any such
2D imaging approach soon became evident because
the aortic annulus is typically ovoid in shape; its
sagittal diameter is generally smaller than itscoronal (left-to-right) diameter, which cannot be
reliably measured by any 2D technique, including
echocardiography.
Although valve sizing based on 2D TTE may be
adequate in many cases and may be improved by
using 2D and 3D TEE, contrast-enhanced multislice
computed tomography has become the gold stan-
dard for TAVR-speciﬁc aortic root assessment. A
CT-derived annular perimeter or annular area
rather than an annular diameter has become the
primary means of valve sizing before TAVR in many
centers.
TTE FOR INTRAPROCEDURAL TAVR GUIDANCE.
Although ﬂuoroscopy remains the principle imaging
tool for proper placement of percutaneous valves,
echocardiography—either TTE or TEE—plays an
important ancillary role in procedural guidance.
FIGURE 4 Fusion Imaging
After transaortic valve replacement with CorValve (Medtronic, Minneapolis, Minnesota), transesophageal echocardiography color ﬂow Doppler
(A and B) images are fused in real time with the ﬂuoroscopy images (C). Abbreviations as in Figure 2.
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365Although TTE has only recently started to replace TEE
in guiding TAVR, TTE already has an established role
in guiding another aortic valve procedure, namely
balloon aortic valvuloplasty (12). During TAVR, in
properly selected patients with good imaging win-
dows, TTE can demonstrate the exact location and
performance of the prosthesis within the aortic root,
its impact on the mitral valve and surrounding car-
diac structures, and the potential need for reposi-
tioning of the aortic prosthesis.
2D TTE can demonstrate whether a deployed
prosthesis assumed its proper circular shape in the
short axis and whether the ventricular end of the
prosthesis is too high or too low relative to the LVOT
in the long axis. Standard TTE semiquantitative
color and spectral Doppler techniques can then be
used to assess TAVR function, including prosthetic
gradients and presence or absence of transvalvular
and perivalvular aortic regurgitation (PAR). When
assessing PAR by TTE, one should bear in mind that
on parasternal long-axis views, posteriorly locatedPARs may be shadowed by the prosthesis; alternative
(especially short-axis) views should be employed for
surveillance of posterior PARs.
TTE FOR SURVEILLANCE OF POSSIBLE TAVR
COMPLICATIONS. Intraprocedural TTE can provide
immediate information on all major TAVR complica-
tions, such as prosthetic malposition and malfunc-
tion, new mitral regurgitation (due to TAVR-related
impingement of the anterior mitral leaﬂet or sec-
ondary to mitral valve disruption by TAVR deploy-
ment hardware), new right or left ventricular wall
motion abnormalities, pericardial effusion with or
without tamponade, and new cardiac shunt (such as
ventricular septal defect or aortic annular rupture).
Using standard echocardiography techniques, TTE
may also be used to guide pericardiocentesis should
tamponade develop during TAVR (13). TTE is also the
primary imaging tool for follow-up evaluation of
TAVR in a manner similar to follow-up of surgically
implanted prostheses.
TABLE 1 TTE Versus TEE in TAVR Guidance
TTE TEE
Procedure invasiveness  Noninvasive  Semi-invasive
Sedation requirement during TAVR  Moderate sedation  General anesthesia
Imaging advantages  2D & Doppler TTE is the primary means for quantitative
and qualitative assessment of aortic stenosis and
its impact on cardiac anatomy and function
 Provides diagnostic, TAVR-relevant information with
a potentially better safety proﬁle compared with TEE
 Provides higher image resolution than TTE
 3D TTE has signiﬁcant incremental value
Imaging disadvantages  Quality of imaging determined by availability and location
of imaging windows
 Imaging may be limited by obesity, hyperinﬂation of
lungs, chest deformity, and supine position
 3D TTE typically has limited incremental value
 Shadowing of posterior PARs by TAVR prosthesis may occur
 TEE imaging may lead to injuries of oropharynx,
esophagus, and the stomach
Potential for disruption of surgical
ﬁeld sterility
 Present but can be minimized with the use of sterile
TTE probe covers
 Minimal
Impact of TAVR vascular access point
to echocardiographic imaging
 Best suited for percutaneous transfemoral TAVR approach  Can be provided with any TAVR access point
2D ¼ 2-dimensional; 3D ¼ 3-dimensional; PAR ¼ perivalvular aortic regurgitation; TAVR ¼ transcatheter aortic valve replacement; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic
echocardiography.
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366What is the proof that TTE can effectively replace
TEE in TAVR guidance? In this issue of iJACC, Sen-
gupta et al. (14) provide initial evidence from a retro-
spective study that TTE coupled with MOC allows for
shorter procedure time while being noninferior with
respect to procedural success, degree of paravalvular
regurgitation, need for valve replacement, or compli-
cation rates compared with TEE under GA.
CHALLENGES IN SUBSTITUTING TTE FOR TEE IN
TAVR GUIDANCE. There is no doubt that in most
instances, TEE may provide higher quality images
than TTE, given the higher frequency of TEE
versus TTE probes and given the potential for a
larger incremental value of 3D TEE compared with
3D TTE imaging in the context of TAVR (15).
However, TEE remains a semi-invasive procedure
and carries a small, but real, risk of serious
oropharyngeal and gastroesophageal complications
that can be particularly devastating in TAVR pa-
tients, who are typically very elderly with multiple
comorbidities.
Challenges in replacing TEE with TTE for TAVR
monitoring include image quality, potential impact
on sterility of the operative ﬁeld, and potential lack of
physician expertise in performing TTE imaging.
Limitations to TTE imaging are well known and
include obesity, hyperinﬂated lungs, and chest de-
formities. Proper selection of patients with good im-
aging windows before TAVR is essential for a
successful periprocedural use of TTE. Because virtu-
ally all TAVR candidates have already had a TTE done
pre-procedurally to assess eligibility, such TTEs
should be reviewed by an echocardiographerplanning to use TTE periprocedurally for adequacy of
transthoracic imaging windows.
Additionally, one should bear in mind that
standard TTE imaging (as performed, for instance, for
pre-procedural TAVR planning) is done in the left
lateral decubitus position. By contrast, during TAVR,
the patient is in a supine position; to ﬁnd the opti-
mum location of parasternal and apical windows the
TTE probe often needs to be placed more laterally in
supine patients compared with those imaged in the
left lateral decubitus position.
The location of the vascular access for TAVR may
limit available TTE imaging windows either directly
through space competition or indirectly via the size
of the sterile ﬁeld necessary for TAVR per-
formance. Of all approaches, percutaneous trans-
femoral approach—which is the most commonly
used TAVR access site—has least interference with
TTE imaging windows and is thus the preferred
setting for using TTE in guiding TAVR. Surgical
femoral cutdowns require larger sterile ﬁelds
compared with transcutaneous femoral approaches,
which then may limit the amount of TTE imaging
windows. At the other extreme is the transapical
TAVR approach, which essentially precludes TTE
guidance. Similarly, direct transaortic or trans-
subclavian may severely limit the number of TTE
imaging windows.
Echocardiographers must take every precaution to
prevent contamination of the sterile ﬁeld in the
operating suite. Whenever there is a potential for
ﬁeld contamination, a commercially available sterile
plastic cover for TTE probe should be used. The
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367emerging technology of robotic TTE (16) may provide
imaging that minimizes interference with other
members of the TAVR team while maintaining ste-
rility of the surgical ﬁeld.
A special challenge may be faced by physician
echocardiographers in the United States, where TTEs
are typically done by sonographers rather than phy-
sicians. The need for immediate and accurate inter-
pretation of TTE images during TAVR typically
requires the presence of a physician echocardiog-
rapher in a TAVR suite. If TTE images are acquired by
such physicians, they need to have proper training
and experience in performing TTEs.
CONCLUSIONS. The type of anesthesia during TAVR
plays an important role in the overall choice of
periprocedural imaging technique. It runs the gamut
from moderate sedation guided with TAVR guided
by ﬂuoroscopy and angiography alone without any
echocardiography at one extreme to GA with endo-
tracheal intubation enabling 2D/3D TEE-guided
TAVR on the other extreme. With the overall
movement in many TAVR centers away from GA,
intraprocedural TTE is well suited for a middle-
ground approach of noninvasive TTE imaging
using moderate sedation (17). Such an approach may
minimize complications in TAVR patients, who
are typically very elderly and frail with multiple
comorbidities.Fluoroscopy-Guided TAVR
Albert M. Kasel, MD, Anupama Shivaraju, MD,
Antonio Colombo, MD, Adnan Kastrati, MD
Since its ﬁrst use in 2002, transcatheter aortic valve
replacement (TAVR) as a treatment modality for severe,
symptomatic aortic valve (AV) stenosis has undergone
numerous modiﬁcations. At present, there are many
percutaneous valves in clinical application and many
more under investigation. The advancement in tech-
nology and innovative implantation techniques have
allowed an increasing number of patients to beneﬁt
from transcatheter heart valves (THV). The purpose of
this work is to describe how to perform a transfemoral
TAVR under ﬂuoroscopic guidance with a minimalistic
approach using mainly the third-generation Edwards
Sapien 3 valve (Edwards Lifesciences, Irvine, California)
as an example.
OVERVIEW ON PATIENT SELECTION AND SCREENING.
All patients get an electrocardiogram, transthoracic
echocardiogram, a coronary angiogram, and at least
a 64-slice, multidetector computed tomography
angiogram (CTA) of the heart, thoracic/abdominalaorta, and bilateral lower extremity arterial vascula-
ture before the TAVR procedure. The CTA is used to
assess the feasibility of the TAVR based on the valve
and vascular anatomy and to measure the aortic
annulus size using the technique described by Kasel
et al. (18).
GENERAL ANESTHESIA AND CONSCIOUS SEDATION
VERSUS LOCAL AND CENTRAL ANALGESICS. Many
studies have shown that TAVR can be safely and
effectively performed with the use of local anesthesia
with conscious sedation (19–23). The advantages
of performing TAVR under local anesthesia with
conscious sedation when compared with general
anesthesia include the following: ability to perform
TAVR on patients with extensive pulmonary disease,
better hemodynamic control and assessment, prompt
assessment and treatment of stroke and myocardial
infarction, early patient mobility, reduction in pro-
cedure time, decreased labor cost, and decreased
hospital stay (22–25). However, a disadvantage to
deep conscious sedation is that the patient can get
disoriented, become restless, and move during the
procedure leading to potential complications. On the
other hand, Kasel et al. (21) showed that TAVR per-
formed using only local and central analgesics is safe
and feasible; full consciousness allows for better
communication with the patient and less movement
during the procedure.
KEY STEPS OF FLUOROSCOPIC-GUIDED TAVR.
1. Place an angled pigtail catheter in the right coronary
cusp via the contralateral access site. Obtain the
perpendicular implantation view under ﬂuoros-
copy using the “right cusp rule” (26) (A. Shivaraju,
unpublished data, February 2015) (Figure 5A). The
pigtail serves as a marker in the right coronary cusp
until the valve is deployed; this reduces the use of
contrast. When available, use the CTA-predicted
implantation angle, which may often need to be
adjusted under ﬂuoroscopy guidance.
2. The vascular access site for the THV sheath is
determined after reviewing the CTA images. Select
a spot on the artery, without calciﬁcation, to
puncture. The femoral head can be used as an
anatomical marker. Access to the common femoral
artery can be performed under ﬂuoroscopy to
ensure the needle is entering the artery above
the bifurcation and below the inguinal ligament, in
most cases at the middle portion of the femoral
head. Percutaneous closure of the puncture site
can be safely done using 2 Perclose ProGlide su-
tures (Abbott Vascular, Abbott Park, Illinois); the
sutures are placed parallel to the course of the
vessel (21).
FIGURE 5 Implantation View and Valve Positioning
(A) Root angiogram showing the perpendicular implantation view obtained using the right cusp rule (26). (B) The angled pigtail in the right
coronary cusp serves as a marker during the alignment of the THV prior to implantation. The double ﬂex mechanism of the Edwards Commander
Delivery System enables for better coaxial alignment (a). The counterclockwise rotation of the delivery system (maximal 180) will bring the
valve in a more posterior and coaxial position (b). Fine adjustment of the valve height is achieved by turning the dedicated wheel on the
delivery system (c). The central marker on the valve is positioned in the red placement zone (d). (C) Depicts the 6-mm zone for placement of
the valve’s central marker (3 mm length) along with its positioning along the black, dotted annulus line. LAO ¼ left anterior oblique;
RAO ¼ right anterior oblique.
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3683. To cross the stenotic AV, use the implantation
view, direct the Amplatz-1 catheter toward the
posteriorly located noncoronary cusp. Subse-
quently, move the straight-tip wire toward the
middle of the AV via slow rotation of the catheter
clockwise until the wire crosses the AV and drops
into the left ventricle (27).
4. In cases with minimal calciﬁcation on the AV,
directly crossing the valve with the THV without
previous balloon aortic valvuloplasty is feasible
(28,29). In cases with a severely calciﬁed AV, a
small balloon could be used for AV pre-dilation as
an alternative to the traditional balloon aortic
valvuloplasty to ensure easy passage of the THV
(A. Shivaraju, unpublished data, February 2015).
5. Prior to implantation, align the THV using the
pigtail catheter as a marker. The double ﬂex
mechanism of the Edwards Commander Delivery
System (Edwards Lifesciences) will enable better
coaxial alignment and positioning of the THV at
the aortic annulus. In addition, the implantation
height of the THV could be ﬁne-tuned using the
dedicated wheel at the grip of the commander
catheter system (Figures 5B and 5C).
6. After valve deployment, in the coaxial view, assess
the position of the valve in relation to the aortic
annulus and coronary ostia, and perform a rootangiogram with 10 ml of contrast volume with a
ﬂow rate of 10 ml/s (Figure 6A). Then, rotate
the C-arm to a right anterior oblique 30 angle
and perform another root angiogram with 30 ml
of contrast volume at a ﬂow rate of 20 ml/s
(Figure 6B). Check for paravalvular aortic regurgi-
tation using the simpliﬁed angiographic classi-
ﬁcation described ﬁrst by Sandler et al. (30)
(Figure 6C). In case of signiﬁcant paravalvular
regurgitation, post-dilation of the THV should
be considered. Use the aortic regurgitation index
(31) or a transthoracic echocardiogram for further
assessment of the aortic insufﬁciency.
A detailed, stepwise instruction for transfemoral
TAVR under ﬂuoroscopy guidance for the Sapien XT
(Edwards Lifesciences) device has previous been
described by Kasel et al. (21).
FLUOROSCOPY-GUIDED TAVR USING THE MEDTRONIC
CORE VALVE. Outlined here are some of the differ-
ences in the implantation of the self-expanding
Medtronic Core Valve (MCV) system (Medtronic,
Minneapolis, Minnesota). First, the deployment of
the MCV begins at the noncoronary side, therefore,
the pigtail catheter should be placed in the non-
coronary cusp for guidance. Next, in most cases,
direct crossing of the AV with the MCV is possible
FIGURE 6 Coaxial Assessment of Valve Position and Aortic Regurgitation
(A) Coaxial assessment of the valve position in relation to the aortic annulus and coronary ostia. (B) Angiographic evaluation of aortic
regurgitation (AR) in the right anterior oblique (RAO) 30 angle. (C) Modiﬁed angiographic classiﬁcation of AR: 1) Density of contrast is lower
than in the aortic root: green zone: trivial or mild insufﬁciency (#I degree), red zone: signiﬁcant insufﬁciency (>I degree). 2) Contrast density is
the same as in the aortic root: signiﬁcant insufﬁciency (>I degree).
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Nevertheless, to ensure a complete expansion of
the MCV, a pre-dilation of the stenotic AV is recom-
mended. Finally, deployment of the MCV can be done
without rapid pacing. However, slow or rapid pacing
will be beneﬁcial and should be used in circumstances
where there is increased valve movement during
placement of this THV.
LIMITATIONS OF THE MINIMALISTIC APPROACH.
First, there is no transesophageal echocardiography
guidance during the procedure to assess for intra-
procedural or immediate post-procedural compli-
cations including pericardial effusion/tamponade,
aortic regurgitation, and injury to the mitral appa-
ratus. However, both ﬂuoroscopy/angiography and
transthoracic echocardiogram may resolve many of
these diagnostic issues. Second, if the patient goes
into respiratory distress, then they will need to be
intubated during the procedure. Third, impaired
renal function can limit the use of contrast, although
TAVR under ﬂuoroscopy guidance can generally
be performed with <100 ml of contrast use. Fourth,
the procedure will need to be done in a timely manner
as the patient will not tolerate lying ﬂat on the table
for long periods of time. Finally, rapid pacing will have
to be done in short intervals to avoid the patient losing
consciousness and to avoid myocardial stunning.
CONCLUSIONS. The minimalistic, ﬂuoroscopic ap-
proach for TAVR allows for the procedure to be
safely and effectively performed in the cardiaccatheterization laboratory setting. In addition, this
approach reduces the procedure time, length of stay
in the intensive care unit and hospital, as well as total
cost. Further device developments in the ﬁeld will
additionally promote the use of the minimalistic,
ﬂuoroscopic approach as the standard TAVR
approach.
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